What is the fair value of Scilex Holding Co (NASDAQ-SCLX) stock?

The current fair value estimate for Scilex Holding Co (NASDAQ-SCLX) is $6.49. This implies an estimated upside of 21.4% versus the current market price.

Is Scilex Holding Co (NASDAQ-SCLX) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 21.4% versus the current market price.

How is the financial health of Scilex Holding Co?

The current financial health read for Scilex Holding Co (NASDAQ-SCLX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Scilex Holding Co's next earnings date?

The next earnings date currently listed for Scilex Holding Co (NASDAQ-SCLX) is November 13, 2026.

Does Scilex Holding Co (NASDAQ-SCLX) pay dividends?

Based on the current data, dividend yield is 58.1%.

What is the market capitalization of Scilex Holding Co?

The current market capitalization listed for Scilex Holding Co is 37.636 M.

What is the enterprise value of Scilex Holding Co?

The current enterprise value listed for Scilex Holding Co is 77.799 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Scilex Holding Co?

The ticker symbol for Scilex Holding Co is NASDAQ-SCLX, and the stock is listed on NASDAQ.

Where is Scilex Holding Co (NASDAQ-SCLX) listed?

Scilex Holding Co (NASDAQ-SCLX) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Scilex Holding Co?

The current debt-to-total-capital ratio listed for Scilex Holding Co is 75.6%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Scilex Holding Co?

The free float listed for Scilex Holding Co is 80.9%. Free float helps investors understand how much of the share base is available for public trading.

Scilex Holding Co (SCLX) Fair Value & Stock Analysis

Scilex Holding Co (SCLX)

Scilex Holding Co is a healthcare company focused on non-opioid therapies for acute and chronic pain. The company markets ZTlido, a topical lidocaine prescription product for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution for the acute treatment of migraine in adults; and GLOPERBA, a liquid oral colchicine product used to help prevent painful gout flares. Scilex is also advancing several development-stage programs, including SP-102 (SEMDEXA) for lumbosacral radicular pain or sciatica, SP-103 for chronic neck and low back pain, and SP-104 for fibromyalgia. In addition, the company has collaboration agreements with Oishi and Itochu for lidocaine tape products and with Lifecore Biomedical for clinical trial material manufacturing and development services related to SEMDEXA. Scilex is based in Palo Alto, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-SCLX	$6.49	21.4% Upside	Undervalued	Not available	Not available	Weak	58.1%	November 13, 2026	1.1x	37.636 M	77.799 M	75.6%	80.9%	-16.4	4.0%